Cocaine Abuse Clinical Trial
Official title:
Effect of Clonidine on Responses to Imagery Scripts
Verified date | July 8, 2014 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
- Research has shown that clonidine, a drug originally prescribed to treat high blood
pressure and some symptoms of opioid withdrawal, can help block stress-induced relapse to
heroin and cocaine seeking in rats. However, it does not seem to block cue-induced relapse in
rats. Researchers are interested in studying whether clonidine shows the same pattern of
effects on stress- and cue-induced cravings for heroin or cocaine in humans.
Objectives:
- To compare the ability of clonidine to reduce stress- and cue-induced cocaine and heroin
craving in drug abusers.
Eligibility:
- Individuals between 18 and 55 years of age who are current cocaine or heroin users.
Design:
- This study will consist of two visits: a screening visit to determine eligibility and an
experimental/script session.
- Before the script session, participants will provide urine and breath samples for
testing. Participants will complete questionnaires to measure their current drug craving
and days since last use of cocaine or heroin.
- At the start of the script session, participants will receive a dose of clonidine or
placebo as directed by the study researchers. Three hours after dosing, participants
will be read four scripts (two neutral, one stress-inducing, and one drug-cue-related)
with breaks in between each script. After each script, participants will respond to
questions about levels of stress and craving.
- Participants will provide saliva samples immediately before and during the script
readings, and will also be measured for skin response to the scripts.
Status | Completed |
Enrollment | 92 |
Est. completion date | August 7, 2013 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
- INCLUSION CRITERIA: 1. Age between 18 and 55; 2. Evidence of current cocaine and/or heroin use (by self-report) with a minimum lifetime drug-use duration of 1 year and a minimum current drug use of once in the last 30 days; EXCLUSION CRITERIA: 1. Hypersensitivity to clonidine or any component of the formulation 2. Schizophrenia or any other DSM-IV psychotic disorder; history of anxiety disorder, panic disorder, bipolar disorder; current Major Depressive Disorder 3. Current physical dependence on opioids, cocaine, alcohol, benzodiazepines or other sedative-hypnotic; this is an exclusion criterion because we want to evaluate the ability of clonidine to affect stress- and cue-induced drug craving independent of its effects on drug withdrawal 4. Cognitive impairment severe enough to preclude informed consent or valid responses on questionnaires 5. Pregnancy or breast feeding 6. Severely impaired hepatic function 7. Severely impaired renal function, with CLcr < 10 ml/minute 8. Medical conditions that contraindicate or that could complicate clonidine administration: 1. hypotension (SBP <95 or DBP < 40 mm Hg) over several readings 2. hypertension(SBP >160 mm Hg, DBP >95 mm Hg) over several readings 3. orthostatic hypotension over several readings or as a consequence of any underlying medical disorder (e.g., autonomic insufficiency) 4. bradycardia (heart rate < 50 bpm) over several readings 5. cerebrovascular disease or any history of CVA or transient ischemic attack (TIA) 6. documented coronary disease 7. serious arrhythmia or conduction defect (e.g., second or third degree heart block, atrial fibrillation) 8. sinus node dysfunction, severe bradycardia or symptomatic bradycardia 9. congestive heart failure 9. Medications that could interact adversely with clonidine: antipsychotics; antihypertensives (e.g., beta blockers); antiepileptics; CNS depressants (e.g. barbiturates, benzodiazepines, narcotic analgesics, alcohol, or other sedatives); cyclosporine; oral hypoglycemic agents or insulin; levodopa; tricyclic antidepressants; herbals such as dong quai, ephedra, yohimbe, ginseng, valerian, St. John s wort, kava kava, gotu kola 10. Women who are able to get pregnant and are not abstinent from sexual activity must agree to use a medically effective form of contraception while in the study. Those include: 1. Hormonal contraceptives (birth control pills, injectable hormones, vaginal ring hormones), 2. Surgical sterility (tubal ligation or hysterectomy) 3. IUD 4. Diaphragm with spermicide 5. Condom with spermicide Women who do not agree to use these medically effective forms of contraception while in the study will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | National Institute on Drug Abuse | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute on Drug Abuse (NIDA) |
United States,
Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E. Effects of clonidine and diazepam on the acoustic startle response and on its inhibition by 'prepulses' in man. J Psychopharmacol. 1997;11(1):29-34. — View Citation
Benschop RJ, Jacobs R, Sommer B, Schürmeyer TH, Raab JR, Schmidt RE, Schedlowski M. Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. FASEB J. 1996 Mar;10(4):517-24. — View Citation
Berger SP, Hall S, Mickalian JD, Reid MS, Crawford CA, Delucchi K, Carr K, Hall S. Haloperidol antagonism of cue-elicited cocaine craving. Lancet. 1996 Feb 24;347(9000):504-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective ratings of drug craving and mood | 1 hr | ||
Primary | Autonomic response (galvanic skin response [GSR]) | 1 hr | ||
Primary | Heart rate and blood pressure | 1 hr | ||
Primary | Endocrine responses (salivary cortisol and salivary alpha-amylase) | 1 hr |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT00217997 -
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
|
N/A | |
Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
Completed |
NCT00227903 -
Therapeutic Substance Abuse Treatment in Pregnancy - 1
|
Phase 2 | |
Terminated |
NCT00142883 -
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
|
N/A | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Completed |
NCT01651377 -
Pramipexole as a Treatment for Cocaine Dependence
|
Phase 1 | |
Recruiting |
NCT00439049 -
Substance Abuse Pre-Treatment Screening Study
|
||
Completed |
NCT00249457 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2
|
N/A | |
Completed |
NCT01401270 -
Prize Contingency Management for Cocaine-Dependent Methadone Patients
|
N/A | |
Completed |
NCT00350610 -
Computer-Based Training in Cognitive Behavior Therapy
|
Phase 1 | |
Recruiting |
NCT06177860 -
Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use
|
||
Completed |
NCT02393599 -
Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin
|
Phase 1 | |
Completed |
NCT02141620 -
n-Acetylcysteine and Cocaine
|
Phase 0 | |
Recruiting |
NCT00218023 -
Medications for Stopping Cocaine Dependence and Preventing Relapse
|
Phase 2 | |
Completed |
NCT00218075 -
Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence
|
Phase 2 | |
Recruiting |
NCT05857852 -
Low-Intensity Focused Ultrasound for Cocaine Use Disorder
|
N/A | |
Completed |
NCT00606801 -
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users
|
N/A | |
Completed |
NCT00292123 -
Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse
|
Phase 1 | |
Completed |
NCT01651364 -
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence
|
Phase 1 |